083790.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:30):

Stats
Today's Volume	105 957
Average Volume	401 302
Market Cap	240.35B
EPS	KRW0 ( 2024-02-25 )
Next earnings date	( KRW0 ) 2024-05-13
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.67 (0.24%)

Volume Correlation

Long: 0.21 (neutral)

Short: -0.26 (neutral)

Signal:(48.299) Neutral

CrystalGenomics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CrystalGenomics, Inc. Correlation - Currency/Commodity

0.38
( neutral )

-0.10
( neutral )

-0.74
( moderate negative )

-0.04
( neutral )

0.68
( moderate )

0.13
( neutral )

CrystalGenomics, Inc. Financials

Annual	2023
Revenue:	KRW17.46B
Gross Profit:	KRW9.07B (51.96 %)
EPS:	KRW132.36

Q3	2023
Revenue:	KRW5.69B
Gross Profit:	KRW3.00B (52.71 %)
EPS:	KRW46.46

Q1	2023
Revenue:	KRW4.09B
Gross Profit:	KRW2.15B (52.47 %)
EPS:	KRW34.12

Q4	2022
Revenue:	KRW3.69B
Gross Profit:	KRW1.93B (52.29 %)
EPS:	KRW24.64

Financial Reports:

No articles found.

CrystalGenomics, Inc.

CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.